OXFORD, Miss., Jan. 29, 2007 (PRIME NEWSWIRE) -- Modern Technology Corp. (Pink Sheets:MODC), a bioscience technology development and acquisition company, announced today its new operations unit, Insight Medical Group, released its business plan for its AnuCyte Cancer Detection System.
The document covers our plans, assumptions, risk, target markets and revenue models and is intended to demonstrate Management's extensive research and basis for claims as well as provide important information for all stockholders or prospective stockholders. The document is extensively referenced and all claims are clearly demonstrated and explained.
The plan is available for download at the following web link:
http://www.insightmedicalgroup.com/library/IMGPLAN.pdf
Anthony Welch, Chairman, said, "As stockholders will see, our plans are well thought out, extensively referenced, and all of our claims and projections have a very clear basis demonstrated in multiple ways throughout the document. We want everyone to see and understand the profound nature of what we now do. I encourage every stockholder and prospective stockholder to read the document thoroughly. I daresay they will be hard pressed to find a more thoroughly referenced document or feel wanting for a more reasonably constructed revenue model. Also, we will soon release an update on our prospective funding for the cancer detection system as well as an update on the details of the InMarketing divesture."
About the AnuCyte Cancer Detection System
The AnuCyte Cancer Detection System is an automated machine that can rapidly detect any form of cancer. The system accurately identifies cancer at any stage in its development and also identifies healthy cancer-free cells in the same test within the same sample. The system eliminates heretofore unreliable, subjective, and error-prone pathology detection of cancer and delivers an automated and objective measurement of the presence or absence of cancer. The AnuCyte system is the first and only system in the world that uses the measurement of advanced chromosomal imbalance as the primary or sole means of detecting cancer. System testing in collaboration with the Cleveland Clinic and Texas Southwestern University demonstrated AnuCyte to successfully detect cancerous and precancerous cells in hundreds of cervical samples and scores of fine needle aspirates from breast tumors. The company is not aware of any automated system in the world more accurate, or even close to AnuCyte's accuracy.
About AnuCyte's Inventors:
The inventor of the AnuCyte system, Dr. David Rasnick, Ph.D. and his scientific research collaborator, Dr. Peter Duesberg, Ph.D., have been prominent names internationally for many years for their research and publications. On many occasions both have appeared internationally on television, in magazines, newspapers and scientific publications. Peter Duesberg is author of the widely available book, "Inventing the AIDS Virus." Investors may wish to read a recent article in Newsweek concerning the cancer research of Peter Duesberg: http://www.msnbc.msn.com/id/14757547/site/newsweek/
In 1970, Peter Duesberg isolated the first cancer gene through his work on retroviruses and mapped the genetic structure of these viruses. This, and his subsequent work in the same field, resulted in his election to the National Academy of Sciences in 1986. He was also the recipient of a seven-year Outstanding Investigator Grant from the National Institute of Health. He has been invited to become a Honorary Member of the World Innovation Foundation alongside 91 Nobel Laureates. (www.thewif.org.uk)
About Insight Medical Group and Modern Technology Corp.
Insight Medical Group, a wholly owned subsidiary, is a specialized biosciences development company whose mission is to bring world-changing medical technology and research to market in the areas of cancer and AIDS. The AnuCyte Cancer Detection System was invented by Dr. David Rasnick, Ph.D. The technology behind AnuCyte and the chromosomal imbalance theory is the result of 45 years of combined cancer research by Dr. David Rasnick, Ph.D. and Dr. Peter Duesberg, Ph.D., who continues his studies on cancer research at the University of California, Berkeley. Modern Technology Corp., a bioscience technology development and acquisition company, builds revenues through a model continuous growth, strategic acquisitions, and commercialization of nascent technology. MODC is a fully reporting public company with the U.S. Securities and Exchange Commission. For the company's SEC filings, visit www.sec.gov. The company's web address is: http://www.moderntechnologycorp.com.
Safe-Harbor Statement
This press release contains statements (such as projections regarding future performance) that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including but not limited to those detailed from time to time in the Company's filings with the Securities and Exchange Commission.